pantoprazole in the treatment of type 2 diabetes mellitus
- Conditions
- Health Condition 1: null- Type 2 Diabetic patient without any complication
- Registration Number
- CTRI/2011/07/001899
- Lead Sponsor
- PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
?Type-2 DM 5 years duration
?On oral antidiabetic therapy ( Metformin±Sulfonylurea)
?No change in anti-diabetic treatment for the last one month
?HbA1c 8.5%
?Fasting plasma glucose not exceeding 300mg/dL
?Patients willing to provide written informed consent
?Diabetes other than type 2 diabetes mellitus
?Evidence of renal disease (S. creatinine 1.5mg/ml)
? Evidence of liver disease (AST/ALT 3 times normal)
? Pregnant and lactating mothers and women intending pregnancy
?Participation in any other clinical trial with in the last 30 days
?History of any hemoglobinopathy that may affect determination of Glycosylated Hemoglobin
?Treatment with oral anti-diabetic agents (other than metformin or SU) during the 12 weeks before baseline visit
?History of intolerance or hypersensitivity to sulfonylurea or metformin or PPI
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of pantoprazole on HbA1c levelTimepoint: 0 and 3 months
- Secondary Outcome Measures
Name Time Method Effect of pantoprazole on 1.FBG, PPBG, HOMA-IR and Beta-cell function <br/ ><br>2.Serum Gasrin level <br/ ><br>3.Serum GLP-1level <br/ ><br>4.Serum Insulin level <br/ ><br>5.Serum C-peptide levelTimepoint: 0 and 3 months